PO.TB02.01 · 肿瘤生物学

用于区分侵袭性与惰性肾肿瘤的MRI影像组学特征

MRI radiomic features to differentiate aggressive and indolent renal tumors

海报缩略图:用于区分侵袭性与惰性肾肿瘤的MRI影像组学特征
编号 2142 展板 14 时间 4/20 09:00–12:00 区域 Section 28 主讲 HUAN LU, MD
分会场 In Vivo Imaging
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Huan Lu, Salim Rukhsar, Xueqing Yin, Garima Suman, Ashish Khandelwal, Ananth J. Madhuranthakam, Durga Udayakumar

Mayo Clinic, Rochester, MN

摘要 Abstract

中文摘要
肾肿瘤具有高度异质性,范围从良性病变和惰性肾细胞癌(RCC)到高度侵袭性表型。在治疗前准确判定肿瘤侵袭性仍是一项重大的临床挑战。常规MR成像对肿瘤生物学背后的微结构差异缺乏敏感性,而活检受采样误差和肿瘤异质性的限制。影像组学提供了一种无创方法来提取高维特征,这些特征可能捕获生物学相关的模式。在这项经IRB批准的回顾性研究中,我们评估了基于MR的影像组学结合机器学习(ML)以区分惰性和侵袭性肿瘤。分析纳入了82例接受肾切除术的RCC患者(侵袭性,n=56;惰性,n=26)术前临床采集的MR图像。在形态学T2加权图像和对比增强MR图像的四个期相(增强前[PRE]、皮髓质期[CM]、肾实质期[NG]和延迟期[DEL])上,使用3D Slicer手动勾画整个肿瘤的感兴趣区(ROI),经标准化后用于影像组学特征提取(PyRadiomics,v3.1.0)。另外,根据梅奥诊所(Mayo Clinic)确立的组织学分类,将肿瘤分为侵袭性和惰性表型。统计分析采用双侧t检验。基于互信息选择的特征用于ML分类(随机欠采样提升法,RUSBoost),并使用准确率、灵敏度、精确率、特异度、F1评分和曲线下面积(AUC)评估性能。在提取的107个影像组学特征中,以下数量的特征在侵袭性和惰性肿瘤之间显示出统计学显著差异(p < 0.05):CM期(n=19)、NG期(n=24)、DEL期(n=22)和T2加权图像(n=29)。若干特征在对比增强图像中始终存在差异,包括一阶特征(长度、表面积、体积)、GLCM(相关性、IDM、IMC1、IMC2)、GLDM(依赖熵、依赖非均匀性、依赖方差)、GLRLM(灰度非均匀性、游程熵、游程长度非均匀性)、GLSZM(高灰度强调、区域熵)和NGTDM(粗糙度)。使用50例患者(侵袭性,n=31;惰性,n=19)中互信息最高的15个特征,五折交叉验证的RUSBoost分类器在识别侵袭性表型方面达到了准确率0.81、灵敏度0.84、精确率0.87、特异度0.77、F1评分0.85和AUC 0.80。MRI影像组学特征显示出区分侵袭性与惰性肾肿瘤的潜力。使用这些特征的基于ML的分类展现出有前景的准确率。在更大队列中进一步优化和验证,可能有助于指导个体化诊疗,包括对惰性肾肿瘤考虑主动监测。
查看英文原文 English abstract
Renal tumors are highly heterogeneous, ranging from benign lesions and indolent renal cell carcinoma (RCC) to highly aggressive phenotypes. Accurately determining tumor aggressiveness before treatment remains a major clinical challenge. Conventional MR imaging lacks sensitivity to microarchitectural differences underlying tumor biology, and biopsy is limited by sampling error and tumor heterogeneity. Radiomics offers a noninvasive approach to extract high dimensional features that may capture biologically relevant patterns. In this IRB-approved retrospective study, we evaluated MR-based radiomics combined with machine learning (ML) to differentiate indolent from aggressive tumors. Pre-operative clinically acquired MR images obtained from eighty-two RCC patients (aggressive, n = 56; indolent, n = 26) who underwent nephrectomy were included for the analysis. Regions of interest (ROIs) of the entire tumor were manually drawn using 3D Slicer on the morphological T2-weighted images and four phases (pre-contrast [PRE], corticomedullary [CM], nephrographic [NG], and delayed [DEL]) from the contrast-enhanced MR images, normalized, and used for radiomic feature extraction (PyRadiomics, v3.1.0). Independently, tumors were grouped into aggressive and indolent phenotypes based on the established histological classification of Mayo Clinic. Statistical analysis used two-sided t-test. Features selected based on mutual information were used for ML classification (Random Under-Sampling Boosting (RUSBoost)) and performance assessed using accuracy, sensitivity, precision, specificity, F1-score, and area under the curve (AUC). Of 107 radiomics features extracted, the following numbers showed statistically significant differences between aggressive and indolent tumors (p < 0.05): CM phase (n = 19), NG phase (n = 24), DEL phase (n = 22), and T2-weighted images (n = 29). Several features consistently differed among contrast-enhanced images and included first-order (length, surface area, volume), GLCM (correlation, IDM, IMC1, IMC2), GLDM (dependence entropy, dependence non-uniformity, dependence variance), GLRLM (gray-level non-uniformity, run entropy, run-length non-uniformity), GLSZM (high gray-level emphasis, zone entropy), and NGTDM (coarseness). Using the 15 features with highest mutual information across 50 patients (aggressive, n = 31; indolent, n = 19), a five-fold cross-validation RUSBoost classifier achieved accuracy 0.81, sensitivity 0.84, precision 0.87, specificity 0.77, F1-score 0.85, and AUC 0.80 for identifying the aggressive phenotype. MRI radiomics features show potential to differentiate aggressive from indolent renal tumors. ML-based classification using these features demonstrates promising accuracy. Further optimization and validation in larger cohorts, may help guide individualized care, including consideration of active surveillance for indolent renal tumors.
利益披露 Disclosure
H. Lu, None.. S. Rukhsar, None.. X. Yin, None.. G. Suman, None.. A. Khandelwal, None. A. J. Madhuranthakam, Globus Medical Stock. D. Udayakumar, None.

← 返回 AACR 2026 检索